A Metal-Free Method for Producing MRI Contrast at Amyloid-β.

Area of Science:

• Neuroimaging
• Biochemistry
• Medical Diagnostics

Background:

• Alzheimer's disease (AD) is marked by amyloid-beta (Aβ) plaque deposition in the brain.
• Early detection is crucial as significant neurological damage occurs before clinical dementia diagnosis.
• Current MRI contrast agents for Aβ detection rely on gadolinium (GdIII), prompting a need for gadolinium-free alternatives.

Purpose of the Study:

• To demonstrate a novel gadolinium-free method for detecting Aβ using MRI.
• To evaluate a nitroxide-based small molecule for its ability to generate MRI contrast in the presence of Aβ.
• To establish a proof-of-concept for early, noninvasive AD detection.

Main Methods:

• A novel molecule was synthesized, combining a fluorene moiety (high Aβ affinity) with a nitroxide spin label (paramagnetic MRI contrast species).
• The molecule's efficacy was tested on brain specimens from AD model mice and wild-type mice.
• In vivo studies involved injecting the molecule into live mice to assess brain penetration and contrast generation.

Main Results:

• The nitroxide-based molecule successfully produced negative MRI contrast in brain specimens with elevated Aβ levels.
• No significant contrast was observed in specimens from wild-type mice.
• In live mice, the compound demonstrated good brain penetration and contrast generation 24 hours post-injection.

Conclusions:

• This study presents the first demonstration of a nitroxide-based small molecule for MRI contrast enhancement in Aβ-rich brain tissue.
• The developed agent offers a promising gadolinium-free approach for early and noninvasive detection of amyloid plaques.
• This method holds potential for monitoring AD progression and evaluating therapeutic interventions.